TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04033419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: memantine dose~* Week 1: 5 mg dose once daily~* Week 2: 5 mg dose twice daily~* Week 3: 5 mg each morning/10 mg each evening~* Week 4 through the end of Chemotherapy: 10 mg dose twice daily~* Total duration: 12 - 26 weeks (depending on chemotherapy regimen)
Study: NCT00223899

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VCL-IM01 (encoding IL-2) with Electroporation
Description: IL-2-encoding plasmid formulated in phosphate-buffered saline at 0.5 mg/mL, 1.5 mg/mL, and 5.0 mg/mL (VCL-IM01) intratumorally injected and followed by electroporation with Inovio MedPulser® 1.0 cm array with needles up to 3 cm long (one 6-pulse cycle per tumor).
Study: NCT04178980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin in relapsing remitting multiple sclerosis
Description: Simvastatin use as adjuvant thearapy in relapsing remitting multiple sclerosis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin in relapsing remitting multiple sclerosis
Description: Simvastatin use as adjuvant thearapy in relapsing remitting multiple sclerosis
Study: NCT00757731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: milnacipran
Description: hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: milnacipran
Description: hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: milnacipran
Description: hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: hard capsule
Study: NCT02276586

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Horizontal Tooth preparation
Description: Round parallel chamfer diamond burs were used for teeth preparation; coarse first (151 micron) and extra-fine after (25 micron)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertical Tooth preparation
Description: Long flame diamond burs were used for teeth preparation; coarse first (151 micron) and extra-fine after (25 micron)
Study: NCT02662647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m²/day for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m²/day for 5 days
Study: NCT03079479

Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle Strenght assesment
Description: Muscle Strenght assesment of the hip muscles

Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle Strenght assesment
Description: Muscle Strenght assesment of the hip muscles

Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle Strenght assesment
Description: Muscle Strenght assesment of the hip muscles

Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle Strenght assesment
Description: Muscle Strenght assesment of the hip muscles

Intervention type: DIAGNOSTIC_TEST
Intervention: 2D Kinematics Analysis
Description: 2D Kinematics Analysis of the gait

Intervention type: DIAGNOSTIC_TEST
Intervention: 2D Kinematics Analysis
Description: 2D Kinematics Analysis of the gait

Intervention type: DIAGNOSTIC_TEST
Intervention: 2D Kinematics Analysis
Description: 2D Kinematics Analysis of the gait

Intervention type: DIAGNOSTIC_TEST
Intervention: 2D Kinematics Analysis
Description: 2D Kinematics Analysis of the gait
Study: NCT02026063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: Telotristat etiprate tablet (250 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: Telotristat etiprate tablet (250 mg)
Study: NCT00723788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI of the abdomen
Description: Multiple MRI pulse sequences of the abdomen
Study: NCT00264459

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Comparator
Description: Solution for sublingual application containing Placebo. The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter.
Study: NCT00052195

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SRL-172
Description: 5 doses of 0.1mL vaccine or placebo given intradermally over 12-months

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SRL-172
Description: 5 doses of 0.1mL vaccine or placebo given intradermally over 12-months
Study: NCT01578031

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive Airway Pressure During Sleep (ResMed S9 Elite)
Description: Positive airway pressure during sleep (ResMed S9 Elite).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive Airway Pressure During Sleep (ResMed S9 Elite)
Description: Positive airway pressure during sleep (ResMed S9 Elite).

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual care.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual care.
Study: NCT03219073

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS using tDCS device
Description: Active tDCS using tDCS device is a noninvasive brain stimulation technique that utilizes low amplitude direct currents applied via scalp electrodes to apply currents to the brain and modulate the level of cortical excitability. tDCS applied over the dorsolateral prefrontal and motor cortex has been reported to be able to decrease pain sensation and to increase pain threshold in healthy subjects and is effective in reducing central chronic pain in PwMS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM tDCS using tDCS device
Description: SHAM tDCS emulates active tDCS in all but the actual stimulation. Electrodes of the tDCS device are placed in the same place as with active tDCS however no current is activated.
Study: NCT02238847

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WallFlex™ Biliary RX Fully Covered/Uncovered Stent System
Description: Reintervention can occur in Arm 1 or Arm 2 with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WallFlex™ Biliary RX Fully Covered/Uncovered Stent System
Description: Reintervention can occur in Arm 1 or Arm 2 with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System
Study: NCT03887130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral vinorelbine
Description: Oral vinorelbine 60 mg/m² on day 1 \& day 8, for cycle 1, and then 80 mg/m² on day 1 \& day 8, every 3 weeks for subsequent cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m² twice a day (2000 mg/m² daily) from day 1 to day 14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine 1250 mg/m²
Description: Gemcitabine 1250 mg/m² on day 1 \& day 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine 1000 mg/m²
Description: Gemcitabine: 1000 mg/m² on day 1 \& 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m² on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m² on day 1
Study: NCT02182349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA soft gelatin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-BI 201335 NA radiolabelled drug
Study: NCT03687502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur hexafluoride lipid-type A microspheres
Description: Contrast Enhanced Ultrasound of the appendix
Study: NCT04161287

Intervention type: PROCEDURE
Intervention: transcatheter arterial chemoembolization
Description: The hepatocellular carcinoma patients (≤5cm）who received SBRT are devided into two groups: with TACE and SBRT alone.
Study: NCT02497001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI 320/14.4/9.6 μg
Description: Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler \[MDI\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFF MDI (PT003) 14.4/9.6 μg
Description: Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFF MDI (PT009) 320/9.6 μg
Description: Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort® Turbuhaler® (TBH) Inhalation Powder
Study: NCT02080793

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Study: NCT00705263

Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2b (SCH 54031)
Description: Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.

Intervention type: DRUG
Intervention: Ribavirin (SCH 18908)
Description: Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
Study: NCT03898063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 90 DAYS film
Description: the intervention conditions include exposure to a film, 90 DAYS (approx 20 minutes long), an entertainment film detailing a woman's decision to tell her romantic partner that she is HIV-positive.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV pamphlet on disclosure
Description: A standard-of-care brochure given to newly diagnosed HIV patients about the importance of status disclosure
Study: NCT01902732

Intervention type: DEVICE
Group type: OTHER
Intervention: Implantation of valves (IBV)
Description: Implantation of intrabronchial valves in the most emphysematous destroyed and hyperinflated lung lobe improves the elastic recoisl of the samll airways by a reduction in lung volume and thus leading to more ergonomic breathing mechanics and diaphragm function. This positive effect is observed particularly in patients with low interlobar collateral ventilation that can be quantified by CT fissure analysis and/or catheter-based measurement.
Study: NCT02921451

Intervention type: DEVICE
Group type: OTHER
Intervention: Restorelle Smartmesh
Description: Patients will have surgery using the device, Restorelle Smartmesh, for treatment of uterine prolapse.
Study: NCT03423498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: toe-spread-out exercise
Description: The therapeutic intervention lasted 14 days and focused on doing the TSO exercise. This exercise was performed unilaterally under the supervision of a qualified physiotherapist. The starting position of the TSO exercise was the sitting position with the knee joint and hip bent at 90 degrees. The exercise consisted of 3 consecutive phases: dorsiflexion of the toes keeping the metatarsal heads and the heel on the ground, moving the fifth toe down and in a lateral direction, moving the big toe down and abduction. The final position needs to be maintained for 5 seconds. The whole sequence was repeated 200 times a day.
Study: NCT02899156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flumazenil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% normal saline
Study: NCT01864616

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Study: NCT02315924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simultaneous coronary and cerebral intervention
Description: Simultaneous strategy is considered that coronary and cerebral intervention will be performed via the same access and within the same day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: staged coronary and cerebral intervention
Description: Staged strategy was intended that coronary or cerebral intervention will be performed within 7 days from the first procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: staged coronary and cerebral intervention
Description: Staged strategy was intended that coronary or cerebral intervention will be performed within 7 days from the first procedure.
Study: NCT03754907

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endocutter stapler
Description: Endocutter ETS 35, ETS Flex 45 stapler, and the Echelon Flex Powered ENDOPATH Stapler with 2.5- or 3.5-mm staples (Johnson \& Johnson K.K., Tokyo, Japan)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suture material
Description: absorbable suture material is used to perform hand-sewn anastomosis in an end-to-end manner.
Study: NCT01653041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study: NCT02058602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of Idiopathic Pulmonary Fibrosis over a period of up to 6 months
Description: Patients are receiving no treatment on this study and there is no investigational product involved.
Study: NCT01779284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost/timolol therapy
Description: Evaluation of 24-hour pressure efficacy with travoprost/timolol therapy after 3 months of chronic dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost/timolol therapy
Description: Evaluation of 24-hour pressure efficacy with travoprost/timolol therapy after 3 months of chronic dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost/Timolol therapy
Description: Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost/Timolol therapy
Description: Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
Study: NCT03430986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM® VOLUMA® with Lidocaine
Description: Treatment with JUVÉDERM® VOLUMA® with Lidocaine injectable gel with optional treatment 8 weeks later.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM® VOLUMA® with Lidocaine
Description: Treatment with JUVÉDERM® VOLUMA® with Lidocaine injectable gel with optional treatment 8 weeks later.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-treatment control
Description: No treatment during the control period.
Study: NCT03022942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GROUP Costal mobilization & Diaphragm Release
Description: Costal mobilization technique (Rib raising): The patient will be lying. The Therapist supports the last four pulps of both hands at the rib angles, gently traverses the rib angles in the posterior-anterior direction, using the stretcher as a lever to facilitate the elevation of the costal angles. Siting: The Therapist hugs the patient by supporting the ribs of the fingers at the rib angles, gently traverses the rib angles bilaterally in the anterior-lateral direction. Manual Diaphragm Release Technique: The therapist makes manual contact with the underside of the costal border of the common cartilage of the last rib. In the inspiratory phase, the therapist draws the points of contact with both hands in a cephalad direction and slightly Accompanying the movement of the rib cage.
Study: NCT02364336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Study: NCT00522925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS433540
Description: 200mg capsule, once daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule, once daily for 28 days
Study: NCT03022942

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GROUP Manual Diaphragm Release
Description: The therapist makes manual contact with the underside of the costal border of the common cartilage of the last rib. In the inspiratory phase, the therapist draws the points of contact with both hands in a cephalad direction and slightly Accompanying the movement of the rib cage.
Study: NCT01455103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936559 (Anti-PD-L1)
Description: Solution, Intravenous infusion, 1 mg/kg, Every 2 weeks, Up to 2 years, depending on response

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936559 (Anti-PD-L1)
Description: Solution, Intravenous infusion, 3 mg/kg, Every 2 weeks, Up to 2 years, depending on response

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936559 (Anti-PD-L1)
Description: Solution, Intravenous infusion, 10 mg/kg, Every 2 weeks, Up to 2 years, depending on response
Study: NCT05104047

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moxibustion - Traditional (Active)
Description: Traditional Moxibustion (Moxa) is a technique in which the herb, artemisia, in a cigar shape (pole moxa) is lit (burned) and applied over specific acupuncture points which follows a specific protocol aimed at reducing neuropathic lower limb pain/discomfort.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moxibustion - Smokeless - (Active)
Description: Smokeless Moxibustion uses the same technique as traditional moxa however, the moxa is smokeless. Smokeless moxa allows for use in a broad range of treatment settings. The protocol is aimed at reducing neuropathic lower limb pain/discomfort.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Moxibustion
Description: Participants receive Placebo Moxibustion - a protocol that mimics the active protocol but is not active.
Study: NCT03132584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The chemotherapy drugs will be given in the hospital. During the first cycle of treatment, participants will stay in the hospital until their blood counts have recovered after treatment. During cycles 2 and 3, participants may go home after chemotherapy if they are doing well. The length of each cycle is 28 days~- Via IV Day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: * The chemotherapy drugs will be given in the hospital. During the first cycle of treatment, participants will stay in the hospital until their blood counts have recovered after treatment. During cycles 2 and 3, participants may go home after chemotherapy if they are doing well. The length of each cycle is 28 days~* Alemtuzumab will be administered as follows:~  * IV Day 1~ * IV Day 2~ * Target dose IV on Day 3 and 4
Study: NCT01699256

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guideline implementation as usual
Description: Newsletters and Invitation to Meetings

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced guideline implementation strategy
Description: Enhanced guideline implementation strategy
Study: NCT01412957

Intervention type: OTHER
Group type: OTHER
Intervention: Best Supportive Care (BSC)
Description: BSC was defined as the best palliative care available as judged appropriate by the investigator and according to institutional guidelines and could include antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy as clinically indicated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: BSC was defined as the best palliative care available as judged appropriate by the investigator and according to institutional guidelines and could include antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy as clinically indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Administered intravenously
Study: NCT04044833

Intervention type: BEHAVIORAL
Intervention: Health life style behaviour ,
Description: Training: applying Personal Information Form, HLBS-II, and MSQ to the intervention and control groups determined randomly and distributing the Student Follow-up Schedules; c) Providing trainings to the intervention group; d) Monitoring the weights, BMIs, and menstrual symptoms of intervention and control groups; and e) After the Training: Applying HLBS-II and MSQ scales to intervention and control groups, collecting the follow-up schedules, and providing training to the control group and all other students. Trainings: First stage: 120 minutes basic training per week for four weeks (40 minutes on diet, 40 minutes on physical activity, and 40 minutes on menstrual symptoms)

Intervention type: BEHAVIORAL
Intervention: Health life style behaviour ,
Description: Training: applying Personal Information Form, HLBS-II, and MSQ to the intervention and control groups determined randomly and distributing the Student Follow-up Schedules; c) Providing trainings to the intervention group; d) Monitoring the weights, BMIs, and menstrual symptoms of intervention and control groups; and e) After the Training: Applying HLBS-II and MSQ scales to intervention and control groups, collecting the follow-up schedules, and providing training to the control group and all other students. Trainings: First stage: 120 minutes basic training per week for four weeks (40 minutes on diet, 40 minutes on physical activity, and 40 minutes on menstrual symptoms)
Study: NCT00212147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General anesthesia with nitrous oxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia without nitrous oxide
Study: NCT00935389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tripterygium glycosides
Description: The onset dosage should be 30mg/q.d. and can be reduced into 20mg b.i.d if CR obtained in 3 months. Without CR in 3 months, the dosage of 90mg/d will last for another 3 months and then reduced to 60mg/d.
Study: NCT03396094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannulae (HFNC) oxygenation
Description: Delivery of 60L/min of supplemental oxygen for pre-oxygenation and apnoeic oxygenation during rapid sequence intubation using the AIRVO™ 2 Humidifier with Integrated Flow Generator (Fisher \& Paykel Healthcare, Auckland, New Zealand)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-rebreather mask and standard nasal cannula
Description: Pre-oxygenation using non-rebreather mask and apnoeic oxygenation via nasal cannulae at 15L/min
Study: NCT03542058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Participants who are randomized to treatment group will receive carvedilol for a period of 6 month.
Study: NCT03804385

Intervention type: PROCEDURE
Group type: OTHER
Intervention: intercostal tube
Description: surgical operation
Study: NCT01556984

Intervention type: OTHER
Intervention: DSA assay
Description: All patients with diabetic foot perform a DSA assay. Before and after DSA, endothelial function will be measured.